National Cancer Institute
National Cancer Institute U.S. National Institutes of Health

Genitourinary Cancers Steering Committee

The Genitourinary Steering Committee (GUSC) was established in 2008. The GUSC is currently composed of the Steering Committee and three task forces (Prostate Cancer, Bladder Cancer, and Renal Cancer). Members of the GUSC include representatives from the Cooperative Groups with active genitourinary programs, representatives from the prostate, renal, and bladder Specialized Programs of Research Excellence (SPORE) and other translational scientists, community oncologists, biostatisticians, pathologists, patient advocates, and NCI staff.

Mission Statement

The GUSC functions to harmonize an efficient, cost-effective, science-driven, and transparent process that will identify and promote the "Best Science" in genitourinary cancer clinical research by addressing the design and prioritization of phase III trials and large phase II studies.

Roster of Genitourinary Steering Committee (GUSC) members
Robert Dreicer, M.D., Eric Klein, M.D., and Anthony Zietman, M.D., Co-chairs

Task Forces

  • Prostate Cancer: Deborah A. Kuban, M.D., Charles J. Ryan, M.D., Andrew Stephenson, M.D. Co-chairs
  • Bladder Cancer: Dean Bajorin, M.D., Michael Hagan, M.D., Ph.D. and Seth Lerner, M.D. Co-chairs
  • Renal Cancer: Christopher Kane, M.D., Brian Rini, M.D., Victor Reuter, M.D. Co-chairs

Clinical Trial Planning Meetings (CTPMs): Goal of Clinical Trial Planning Meetings, and List of CTPM Executive Summaries and Publications

Active Protocols

CCCT Contact: Abdul Tawab-Amiri, Ph.D.